METASTATIC ENDOMETRIAL CANCER
Clinical trials for METASTATIC ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for METASTATIC ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis is the first study in people to test a new oral medication called NKT3964. The main goals are to find a safe dose and see if the drug shows early signs of shrinking tumors in adults with advanced cancers that have spread and no longer respond to standard treatments. The stud…
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New Two-Drug attack on Tough-to-Treat cancers begins human testing
Disease control Recruiting nowThis early-stage trial is testing the safety and initial effectiveness of a new oral drug, STC-15, when given alongside an existing immunotherapy called toripalimab. It will enroll about 188 adults with specific advanced cancers—including lung, melanoma, endometrial, and head/nec…
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough cancers: first human trial of experimental drug begins
Disease control Recruiting nowThis is the first human study of an experimental drug called ERX-315 for people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will also look for earl…
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: EtiraRx Australia Pty Ltd • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC